China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval from the National Medical Products Administration (NMPA) for its GenSci120 in rheumatoid arthritis (RA). The monoclonal antibody (mAb) was previously approved for studies in adult systemic lupus erythematosus, adult primary Sjogren’s syndrome, and inflammatory bowel disease in China.
Mechanism of Action
The Category 1 biologic product binds to PD-1 and activates the PD-1 inhibitory signaling pathway and antibody-dependent cellular cytotoxicity (ADCC) effect. This mechanism inhibits or kills pathogenic T cells, thereby exerting a relatively specific targeted immunosuppressive effect. GenSci120 is designed for the treatment of autoimmune diseases.-Fineline Info & Tech
